134 related articles for article (PubMed ID: 38062789)
1. Specific Pathology Features Enrich Selection of Endometrial Carcinomas for POLE Testing.
Keyhanian K; Han L; Howitt BE; Longacre T
Am J Surg Pathol; 2024 Mar; 48(3):292-301. PubMed ID: 38062789
[TBL] [Abstract][Full Text] [Related]
2. POLE and Mismatch Repair Status, Checkpoint Proteins and Tumor-Infiltrating Lymphocytes in Combination, and Tumor Differentiation: Identify Endometrial Cancers for Immunotherapy.
Dong D; Lei H; Liu D; Bai H; Yang Y; Tang B; Li K; Liu J; Xu G; Xiao X
Front Oncol; 2021; 11():640018. PubMed ID: 33816285
[TBL] [Abstract][Full Text] [Related]
3. Molecular Classification of Endometrial Endometrioid Carcinoma With Microcystic Elongated and Fragmented Pattern.
Ju B; Wu J; Sun L; Yang C; Yu H; Hao Q; Wang J; Zhang H
Int J Gynecol Pathol; 2024 May; 43(3):233-241. PubMed ID: 37733028
[TBL] [Abstract][Full Text] [Related]
4. Prognosis of polymerase epsilon (POLE) mutation in high-grade endometrioid endometrial cancer: Systematic review and meta-analysis.
Casanova J; Duarte GS; da Costa AG; Catarino A; Nave M; Antunes T; Serra SS; Dias SS; Abu-Rustum N; Lima J
Gynecol Oncol; 2024 Mar; 182():99-107. PubMed ID: 38262245
[TBL] [Abstract][Full Text] [Related]
5. Blinded histopathological characterisation of POLE exonuclease domain-mutant endometrial cancers: sheep in wolf's clothing.
Van Gool IC; Ubachs JEH; Stelloo E; de Kroon CD; Goeman JJ; Smit VTHBM; Creutzberg CL; Bosse T
Histopathology; 2018 Jan; 72(2):248-258. PubMed ID: 28795426
[TBL] [Abstract][Full Text] [Related]
6. Validation of a one-step genomics-based molecular classifier for endometrial carcinoma in a large Chinese population.
Kang N; Zhang X; Wang Z; Dai Y; Lu S; Su W; Gai F; Zhu C; Shen D; Wang J
Pathol Res Pract; 2024 Feb; 254():155152. PubMed ID: 38277742
[TBL] [Abstract][Full Text] [Related]
7. Tumor-infiltrating lymphocytes and POLE mutation in endometrial carcinoma.
Raffone A; Travaglino A; Raimondo D; Boccellino MP; Maletta M; Borghese G; Casadio P; Insabato L; Mollo A; Zullo F; Seracchioli R
Gynecol Oncol; 2021 May; 161(2):621-628. PubMed ID: 33715893
[TBL] [Abstract][Full Text] [Related]
8. Enrichment for the
Parulekar M; Kim H; Kim K; Ala A
J Gynecol Oncol; 2024 May; 35(3):e94. PubMed ID: 38764327
[No Abstract] [Full Text] [Related]
9. Interpretation of somatic POLE mutations in endometrial carcinoma.
León-Castillo A; Britton H; McConechy MK; McAlpine JN; Nout R; Kommoss S; Brucker SY; Carlson JW; Epstein E; Rau TT; Bosse T; Church DN; Gilks CB
J Pathol; 2020 Mar; 250(3):323-335. PubMed ID: 31829442
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations.
Hussein YR; Weigelt B; Levine DA; Schoolmeester JK; Dao LN; Balzer BL; Liles G; Karlan B; Köbel M; Lee CH; Soslow RA
Mod Pathol; 2015 Apr; 28(4):505-14. PubMed ID: 25394778
[TBL] [Abstract][Full Text] [Related]
11. Histopathological features of endometrial carcinomas associated with POLE mutations: implications for decisions about adjuvant therapy.
Bakhsh S; Kinloch M; Hoang LN; Soslow RA; Köbel M; Lee CH; McAlpine JN; McConechy MK; Gilks CB
Histopathology; 2016 May; 68(6):916-24. PubMed ID: 26416160
[TBL] [Abstract][Full Text] [Related]
12. Mutation spectrum of POLE and POLD1 mutations in South East Asian women presenting with grade 3 endometrioid endometrial carcinomas.
Wong A; Kuick CH; Wong WL; Tham JM; Mansor S; Loh E; Jain S; Vikas NN; Tan SH; Chan SH; Li ST; Chew SH; Hong W; Ngeow J
Gynecol Oncol; 2016 Apr; 141(1):113-20. PubMed ID: 26748215
[TBL] [Abstract][Full Text] [Related]
13. Endometrial Carcinomas With Subclonal Loss of Mismatch Repair Proteins: A Clinicopathologic and Genomic Study.
Mendoza RP; Wang P; Schulte JJ; Tjota MY; Jani I; Martinez AC; Haridas R; Wanjari P; Steinhardt G; Brown N; Betz BL; Chapel DB; Kertowidjojo E; Yamada SD; Bennett JA
Am J Surg Pathol; 2023 May; 47(5):589-598. PubMed ID: 36866757
[TBL] [Abstract][Full Text] [Related]
14. [Comprehensive assessment of mismatch repair and microsatellite instability status in molecular classification of endometrial carcinoma].
Liu Y; Wang YX; Sun XJ; Ting X; Wu R; Liu XD; Liu CR
Zhonghua Fu Chan Ke Za Zhi; 2023 Oct; 58(10):755-765. PubMed ID: 37849256
[No Abstract] [Full Text] [Related]
15.
Kaneko E; Sato N; Sugawara T; Noto A; Takahashi K; Makino K; Terada Y
J Gynecol Oncol; 2021 Nov; 32(6):e79. PubMed ID: 34431253
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive immunomolecular profiling of endometrial carcinoma: A tertiary retrospective study.
Victoor J; Borght SV; Spans L; Lehnert S; Brems H; Laenen A; Vergote I; Van Gorp T; Van Nieuwenhuysen E; Han S; Timmerman S; Van Rompuy AS; Vanden Bempt I
Gynecol Oncol; 2021 Sep; 162(3):694-701. PubMed ID: 34253388
[TBL] [Abstract][Full Text] [Related]
17. Immune signatures of the POLE mutation in endometrial carcinomas: a systematic study based on TCGA data and clinical cohort validation.
Wang T; Yu D; Wang J; Zhu N; Tang XB; Chen X; Su XM; Huang YG
Front Oncol; 2023; 13():1250558. PubMed ID: 38023184
[TBL] [Abstract][Full Text] [Related]
18. Abrupt loss of MLH1 and PMS2 expression in endometrial carcinoma: molecular and morphologic analysis of 6 cases.
Pai RK; Plesec TP; Abdul-Karim FW; Yang B; Marquard J; Shadrach B; Roma AR
Am J Surg Pathol; 2015 Jul; 39(7):993-9. PubMed ID: 25786082
[TBL] [Abstract][Full Text] [Related]
19. Peritumoral granulomatous reaction in endometrial carcinoma: association with DNA mismatch repair protein deficiency, particularly loss of PMS2 expression.
Stewart CJR; Pearn A; Pachter N; Tan A
Histopathology; 2018 Sep; 73(3):428-437. PubMed ID: 29710374
[TBL] [Abstract][Full Text] [Related]
20. Immunological profiling of molecularly classified high-risk endometrial cancers identifies
Eggink FA; Van Gool IC; Leary A; Pollock PM; Crosbie EJ; Mileshkin L; Jordanova ES; Adam J; Freeman-Mills L; Church DN; Creutzberg CL; De Bruyn M; Nijman HW; Bosse T
Oncoimmunology; 2017; 6(2):e1264565. PubMed ID: 28344870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
